ERBB2 (HER2) protein expression in uterine sarcomas

被引：0
作者：
Zafrakas, M. [1 ]
Zepiridis, L. [1 ]
Theodoridis, T. D. [1 ]
Venizelos, I. D. [2 ]
Papanicolaou, A. [1 ]
Agorastos, T. [1 ]
Bontis, J. N. [1 ]
机构：
[1] Aristotle Univ Thessaloniki, Dept Obstet & Gynecol 1, Papageorgiou Gen Hosp, Thessaloniki 56403, Greece
[2] Hippokrateio Gen Hosp, Dept Pathol, Thessaloniki, Greece
来源：
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2009年 / 30卷 / 03期
关键词：
Uterine sarcoma; ERBB2; HER2; Targeted therapy; Trastuzumab; Herceptin (R); Lapatinib; Tykerb (R); METASTATIC BREAST-CANCER; RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; OF-THE-LITERATURE; ADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; TRASTUZUMAB; CARCINOSARCOMA; HER-2/NEU; THERAPY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: Multiple clinical trials in recent years have shown that breast cancer patients with primary tumors overexpressing ERBB2 can be effectively treated with specific forms of modern anti-ERBB2-targeted therapy. The aim of the present study was to analyze the expression of the ERBB2 (HER2) protein in uterine sarcomas, in order to investigate the possibility of applying this treatment modality in uterine sarcomas. Methods: The expression of ERBB2 has been analyzed immunohistochemical in formalin-fixed paraffin-embedded primary uterine sarcomas (n = 11). Results: Using a semi-quantitative immunohistochemical score, we found that ERBB2 expression was very weak in the majority of tumors, with only three sarcomas showing moderate ERBB2 expression. Published studies evaluating the same issue in small numbers of uterine sarcomas reached similar findings. Conclusion: Overall, ERBB2 expression appears to be weak in uterine sarcomas. However, targeted treatment might still be feasible in a subgroup of patients with uterine sarcomas overexpressing ERBB2.
引用
收藏
页码：292 / 294
页数：3
相关论文
共 50 条
  • [21] ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
    Choi, Byung-Kwon
    Fan, Xuejun
    Deng, Hui
    Zhang, Ningyan
    An, Zhiqiang
    CANCER MEDICINE, 2012, 1 (01): : 28 - 38
  • [22] ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy
    McAfee, John L.
    Hoda, Raza S.
    Hoyle, Carrie
    McCoy, Lauren
    Sprague, Cathy
    Reddy, Chandana A.
    Koyfman, Shlomo A.
    Geiger, Jessica L.
    Komforti, Miglena K.
    Griffith, Christopher C.
    MODERN PATHOLOGY, 2023, 36 (10)
  • [23] Inhibition of ErbB2(Her2) expression with small molecule transcription factor mimics
    Lee, Lori W.
    Taylor, Christopher E. C.
    Desaulniers, Jean-Paul
    Zhang, Manchao
    Hojfeldt, Jonas W.
    Pan, Quintin
    Mapp, Anna K.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (21) : 6233 - 6236
  • [24] Prognostic value of ErbB2/HER2 in human meningiomas
    Arnli, Magnus B.
    Winther, Theo L.
    Lydersen, Stian
    Torp, Sverre H.
    PLOS ONE, 2018, 13 (10):
  • [25] Tucatinib HER2 (ErbB2) inhibitor Treatment of breast and colorectal cancer
    Patil, T.
    Shagisultanova, E.
    Borges, V. F.
    DRUGS OF THE FUTURE, 2019, 44 (01) : 11 - 19
  • [26] Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review
    Verschoor, Noortje
    Deger, Teoman
    Jager, Agnes
    Sleijfer, Stefan
    Wilting, Saskia M.
    Martens, John W. M.
    CANCER TREATMENT REVIEWS, 2022, 106
  • [27] HER2 Gene Amplification and Protein Expression in Pancreatic Ductal Adenocarcinomas
    Aumayr, Klaus
    Soleiman, Afschin
    Sahora, Klaus
    Schindl, Martin
    Werba, Gregor
    Schoppmann, Sebastian F.
    Birner, Peter
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2014, 22 (02) : 146 - 152
  • [28] Quantitative proteomic analysis of HER2 protein expression in PDAC tumors
    Randall, Jamie
    Hunt, Allison L.
    Nutcharoen, Aratara
    Johnston, Laura
    Chouraichi, Safae
    Wang, Hongkun
    Winer, Arthur
    Wadlow, Raymond
    Huynh, Jasmine
    Davis, Justin
    Corgiat, Brian
    Bateman, Nicholas W.
    Deeken, John F.
    Petricoin, Emanuel F.
    Conrads, Thomas P.
    Cannon, Timothy L.
    CLINICAL PROTEOMICS, 2024, 21 (01)
  • [29] HER2/ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors
    Smithgall, Marie C.
    Yemelyanova, Anna
    Mathew, Susan
    Gogineni, Swarna
    He, Bing
    Zhang, Taotao
    Robinson, Brian D.
    Tu, Jiangling J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2024, 43 (02) : 134 - 139
  • [30] CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy
    Turcotte, Martin
    Allard, David
    Mittal, Deepak
    Bareche, Yacine
    Buisseret, Laurence
    Jose, Vinu
    Pommey, Sandra
    Delisle, Vincent
    Loi, Sherene
    Joensuu, Heikki
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Sotiriou, Christos
    Smyth, Mark J.
    Stagg, John
    CANCER RESEARCH, 2017, 77 (20) : 5652 - 5663
12345